How TMS Therapy for Depression Works Without Medication

223,000 Patients Treated Without a Single Pill

Over eight million treatment sessions. More than 1,100 practices across the United States. Four separate FDA clearances spanning adult depression, anxious depression, obsessive-compulsive disorder, and adolescent depression. Those numbers belong to a single device that does not use drugs, does not require surgery, and does not involve sedation. Neuronetics, a medical technology company headquartered in Malvern, Pennsylvania, and listed on NASDAQ under the ticker STIM, built NeuroStar Advanced Therapy as a TMS therapy for depression that treats mental health conditions at their neurological source rather than through the body's chemical or digestive systems.

The concept behind the technology is direct. Specific areas of the brain regulate mood. In people with depression, the synapses in those areas become underactive, weakening the connections that support healthy emotional function. Rather than introducing a medication that travels through the bloodstream, NeuroStar delivers focused magnetic pulses directly to the affected brain region to reactivate those dormant connections. CEO Keith J. Sullivan leads the company, which holds the largest clinical dataset of any TMS system for depression, including 15 studies, 31 publications, and two randomized controlled trials.

How TMS Therapy for Depression Works Inside the Brain

NeuroStar uses a proprietary figure-eight coil that focuses magnetic energy with precision on the brain's mood-regulating area. The pulses are similar in strength to those generated by an MRI machine. Each pulse stimulates neurons in the targeted region, reactivating synapses and restoring the brain's ability to regulate neurotransmitter levels. Because the treatment targets one specific brain area rather than circulating through the entire body, it avoids the systemic side effects commonly associated with antidepressant medications. According to NeuroStar, the therapy has no effects on cognition or sleep.

What distinguishes NeuroStar from other TMS devices is a patented technology called Contact Sensing. This system provides continuous real-time feedback in three dimensions during every session. If contact between the coil and the patient's head is compromised at any point, the system immediately alerts the clinician. This ensures the patient receives the exact prescribed dose with every pulse, every session, eliminating variability in treatment delivery. Additionally, NeuroStar offers TouchStar Theta Burst, a newer protocol that uses higher-frequency pulses to reduce session times from the standard 19 to 40 minutes down to approximately three minutes. Providers can add this protocol through a simple software update without purchasing new hardware.

Four FDA-Cleared Indications From a Single TMS Therapy Platform for Depression

NeuroStar's versatility lies in the fact that a single device treats four distinct conditions without requiring hardware upgrades or additional equipment purchases between indications.

The first clearance addressed adult major depressive disorder in patients who had not found sufficient relief from antidepressant medication. Clinical data from this indication showed that 83% of patients completing treatment experienced measurable depression relief, and 62% achieved full remission. Proven effectiveness extended through 12 months in treatment-resistant patients, with a clinical discontinuation rate of only 5%.

The second and third clearances, both granted in the same period, expanded the device to anxious depression and obsessive-compulsive disorder. Anxious depression covers patients diagnosed with major depressive disorder who also experience significant comorbid anxiety symptoms. For these patients, NeuroStar decreases anxiety symptoms alongside treating the underlying depression. For OCD, NeuroStar functions as an adjunct therapy used in combination with medication or behavioral treatment.

The fourth and most recent clearance authorized NeuroStar as a first-line add-on TMS therapy for depression in adolescents aged 15 to 21, making it the first and only TMS device cleared for this age group. Nearly 10,000 adolescents have been treated across over 300,000 sessions. Data presented at a major child psychiatry conference showed nearly 60% of treated adolescents reached remission. Prior clinical studies reported a 78% response rate and 48% remission rate in this population. The FDA reviewed data from the TrakStar registry alongside published literature and concluded that NeuroStar was substantially equivalent in safety and effectiveness as an adjunct to antidepressant therapy.

What a Treatment Session Looks Like and What to Expect

A NeuroStar session takes place in a physician's office, clinic, or hospital. The patient reclines in a comfortable chair while a cushioned coil is positioned precisely against their head. There is no anesthesia and no sedation. The patient remains fully awake and alert throughout. During treatment, they feel a tapping, tingling, or warming sensation where the coil is positioned. This sensation is usually temporary and subsides with subsequent sessions.

A typical treatment course consists of 36 sessions delivered over approximately six weeks, with daily sessions five days per week. With the standard protocol, each session lasts between 19 and 40 minutes. With TouchStar Theta Burst, sessions take approximately three minutes. After each session, the patient can drive home and resume all normal activities immediately. There is no recovery period. The most common side effect is mild to moderate pain or discomfort at or near the treatment site, which typically subsides within the first week of treatment. There is a rare risk of seizure estimated at less than 0.1% per patient. The treatment is not appropriate for individuals with implanted metallic devices in or near the head, and patients with a history of seizures should discuss eligibility with their physician. Most major insurance companies cover NeuroStar for major depressive disorder and anxious depression, with new payors frequently adding OCD coverage.

Where This TMS Therapy for Depression Fits in Mental Healthcare

Mental health treatment has historically relied on two primary tools: psychotherapy and medication. For millions of patients, these options provide meaningful relief. For a significant number, they do not. Antidepressants work through the body's chemical systems, which means they affect not only the brain but also digestion, sleep, weight, and sexual function. For adolescents in particular, the range of approved medications has been extremely limited compared to what is available for adults.

TMS therapy for depression offers a third pathway that works alongside existing treatments rather than replacing them. It targets the brain directly without entering the bloodstream, which is why it avoids the systemic side effects that cause many patients to discontinue medication. NeuroStar is the number one physician-recommended TMS therapy in the United States, backed by the world's largest depression outcomes registry. The same device now treats four conditions across patients ranging from adolescents to older adults, all without requiring different hardware. Whether TMS continues to expand into additional mental health indications will depend on ongoing clinical research. For the conditions it already covers, the clinical data across 223,000 patients and 8.2 million sessions represent one of the most extensively documented non-drug treatment records in mental healthcare.